.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean consequence of 11 months, clients along with metastatic stomach tumors that acquired biomarker-matched therapies based upon distributing growth DNA profiling showed a more significant scientific perk than those receiving unmatched treatment.